Found 482 results in Expert Content

Summary: Catalent’s CEO John Chiminski and Endpoints News’ John Carroll have a virtual fireside chat discussing their predictions for what 2022 has in store for the biopharma industry.

Learn how a biopharmaceutical company partnered with Catalent to develop and manufacture a commercially-viable, patient-friendly, stable tablet for a program intended to treat a disease that has unmet medical need.

Advances in in silico and experimental techniques mean that APIs and prototype formulations can be thoroughly characterised using multiple material-sparing assays, allowing the most promising formulation candidates to move on to in vivo studies.

This article looks at how innovation in the industry-leading Zydis ODT platform is expanding oral formulation options and bringing benefits to patients.

Summary: Integrated Development Offering to Facilitate Adaptive Trials & Accelerate Phase 1

Summary: During this webinar, biopharma R&D professionals will review strategies for moving successfully and efficiently from preclinical studies to first-in-human trials. They will call upon their own experiences to provide advice that will help others in the industry navigate this crucial transition.

This article discusses a systematic approach to ensure tech transfers meet scheduled timelines.

This executive summary provides expert insight on overcoming manufacturing challenges associated with expedited development programs.

Summary: In this webinar, experts provide an overview of the latest trends in manufacturing of oral solid dosage form and discuss key considerations of transitioning an early-stage project to late-stage as well as technology transfer.

This executive summary includes evidence on how the right guidance at the right time can help you create more successful treatments.